Introduction
Phthalates are a group of high-production volume compounds added to plastics to confer flexibility (e.g., vinyl flooring) and used in personal care and other consumer products (1) .
Several phthalates can act as endocrine disruptors, and early life exposure has been associated with adverse neurobehavioral and reproductive effects in children (2) (3) (4) (5) (6) . Numerous studies monitoring phthalate metabolites in urine have shown widespread exposure, including among inner-city populations, with higher concentrations observed among children than adults (7) (8) (9) (10) (11) (12) .
Although phthalates are rapidly metabolized, the ubiquity of their metabolites in urine suggests that exposure occurs nearly constantly with contributions from ingestion, inhalation, and dermal absorption (13) . Personal air concentrations of two phthalates, diethyl phthalate (DEP), which is more volatile than most other phthalates, and butylbenzyl phthalate (BBzP), which is found on respirable particles, were correlated with maternal urinary concentrations of the corresponding metabolites suggesting inhalation as an important route of exposure (8, 11) .
In a cross-sectional case-control analysis of Swedish children ages 3-8 years, di(2-ethylhexyl) phthalate (DEHP) and BBzP in bedroom dust were associated with physician-confirmed asthma and rhinitis, respectively (14) . In a cross-sectional analysis of adults from the National Health and Nutrition Examination Survey (NHANES), urinary concentrations of monoethyl phthalate (MEP), the metabolite of DEP, and metabolites of di-n-butyl phthalate (DnBP) and di-isobutyl phthalate were associated with decreases in forced expiratory volume in 1 sec (FEV 1 ) (15) . While these findings with asthma, rhinitis and airflow obstruction suggest the potential for increased airway inflammation with phthalate exposure, it has not been demonstrated.
The measurement of fractional exhaled nitric oxide (FeNO), a biomarker of subclinical airway inflammation, offers a method to test for associations between phthalate exposure and airway inflammation (16) . Prospective studies in children reported associations of higher FeNO with subsequent exacerbations in asymptomatic asthmatic children after withdrawal of inhaled corticosteroids and increased risk of new-onset asthma among non-asthmatic children (17) (18) (19) .
FeNO is responsive to environmental pollutants that contribute to respiratory health problems.
Exposure to inhalant air pollutants such as respirable particulate matter (PM 2.5 ), black carbon, and formaldehyde, has been associated positively with FeNO (20) (21) (22) (23) . We are unaware of any population-based studies examining the association between phthalates and FeNO. Airway inflammation and FeNO are increased in both seroatopic and asthmatic children; thus these children may be more responsive to exposures that affect airway inflammation.
Based on the prior human observational studies, we hypothesized that higher urinary concentrations of four phthalate metabolites: MEP, mono-n-butyl phthalate (MnBP; the metabolite of DnBP), monobenzyl phthalate (MBzP; the major metabolite of BBzP), and mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP; a metabolite of DEHP) would be associated with higher concurrent FeNO in children. We also hypothesized that children with seroatopy and Page 5 of 44 wheeze, as surrogate measures of allergy and the hyperresponsive airways of asthma, would be more susceptible to airway inflammation triggered by these environmental exposures.
Methods
Participants were selected based on available samples from the Columbia Center for Children's Environmental Health (CCCEH) study, a longitudinal birth cohort that enrolled 727 nonsmoking Dominican and African American pregnant women free of hypertension, diabetes, and known HIV living in Northern Manhattan and the South Bronx (24) . While expectant mothers were recruited from neighborhoods that also had high asthma prevalence (25), women were not recruited based on reported history of asthma or allergy. Children (ages 4.9-9.1 years) included in these analyses provided at least one spot urine sample during an office visit when Phthalate metabolites in urine collected between mid-morning and early evening were measured at the CDC as described (8, 10) . We used urinary concentrations of MEHHP as the proxy for exposure to DEHP (justification in online supplement). Correction factors of 0.66 and 0.72 were applied to the MEP and MBzP concentrations, respectively, to adjust for previous overestimations of the analytic standards (further details in online supplement) (12).
FeNO collection
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FeNO was collected with a modified offline device along with ambient NO as described previously and in the online supplement (26) (27) (28) . FeNO data were excluded if the child reported having a cold at the time of the measurement.
Seroatopy measurement
Seroatopy was defined as specific IgE to dust mite, cockroach, or mouse allergens (≥0.35 IU/ml) by ImmunoCap (Phadia, Uppsala, Sweden) in serum collected within one year of the FeNO measure (29) .
ISAAC wheeze by questionnaire
Mothers were asked whether their child had wheezed in the past 12 months at age 5, 6, 7 and 9 years using the International Study of Allergy and Asthma in Children (ISAAC) questionnaire (30) . Children with a report of wheeze on the questionnaire administered on the day of FeNO collection or at the next study visit (within one year) were classified as having wheezed.
Modeled probability of wheeze
Because reports on single questionnaires may not characterize the episodic and variable timing of wheeze in childhood, a larger set of repeated questionnaires also was used to model the probability of wheezing in the last three months as a continuous measure at each FeNO collection for all n=313 observations. Four childhood wheeze phenotypes (patterns) were identified using latent class growth analysis, and the posterior probabilities of phenotype membership as well as the probabilities of wheezing in each phenotype were estimated for each child in the study at the age of FeNO measurement (31) .
Statistical analysis
Individual children had 1-3 observations with phthalate and FeNO collections; therefore, repeated measures were modeled using generalized estimating equations (GEE) with robust standard errors. Models included specific gravity to adjust for urinary dilution (32) , as well as potential confounders; age, sex, race/ethnicity, time of day of FeNO collection and ambient NO.
Phthalate metabolite, FeNO, and ambient NO variables were log transformed due to the right skew and high variance at the upper range of their distributions. Analyses were conducted using R version 2.13.1 (33) (34) (35) .
Results
The 244 participants included 125 girls and 119 boys (Table 1) . Of the 244 children enrolled who provided at least one measure for both phthalates and FeNO, 65 had two measures, and two children had three, resulting in a total of n=313 paired observations of phthalate metabolites and FeNO. The demographics of the children included in the analyses were similar to those who were enrolled, but excluded from these analyses, except a slightly higher frequency of first-born children (Table E1 in online supplement). Exposures to the phthalates examined were widespread as suggested by the detection of the metabolites of all four phthalates in 100% of urine samples (Table E2 ). The concentrations of the four phthalate metabolites within each sample were positively correlated with a range of pair-wise Spearman's correlations from rho = 0.21-0.68 (See Online Table E3 ).
To characterize predictors of children's phthalate metabolites urinary concentrations, GEE models with age, sex, and race/ethnicity as predictors were fit for each of the four logtransformed metabolite concentrations also including specific gravity as a covariate. The urinary 7 concentrations of three of the metabolites were higher in girls than in boys: MEP (41% higher, 95% CI, 8.0% to 83%, p=0.011), MnBP (32% higher, 95% CI 9.0% to 60%, p=0.005), and MEHHP (45% higher, 95% CI 16% to 81%, p=0.001). There was no significant difference by age or race/ethnicity for the urinary concentrations of any of the metabolites.
Phthalate metabolites and FeNO
FeNO measures ranged from 2.3 to 71.6 ppb with a median of 7.9 ppb and an interquartile range from 5.7 to 12.3 ppb and were approximately log-normally distributed. In a GEE model of FeNO with age, sex, race/ethnicity, time of day and ambient NO concentration as predictors, only ambient NO concentration was significantly positively associated with FeNO. In four separate adjusted models, FeNO was associated with urinary concentrations of MEP, MnBP, and MBzP but not MEHHP, after controlling for specific gravity, age, sex, race/ethnicity, time of day of FeNO collection and ambient NO concentration ( Table 2 ). The effect size for MnBP was slightly larger than for MEP and MBzP although all three were very similar and were consistent with linearity in adjusted models using quintiles of urinary concentrations (Figure 1 ).
For example, there was a 6.8% increase in FeNO (95% CI 1.1% to 12.9%, p=0.019) for each logunit increase in MBzP concentrations, adjusting for covariates. Similarly, a log-unit increase in MEP concentration was associated with a 6.5% increase in FeNO (95% CI 1.0% to 12.4%, p=0.021) adjusted for covariates, while a log unit change in MnBP concentration was associated with a 8.5% increase in FeNO (95% CI 0.2% to 17.6%, p=0.045) adjusting for covariates. Effect estimates of the metabolites on FeNO were altered less than 10% in adjusted analyses including potential confounding variables individually: oral/inhaled corticosteroid use, older siblings, number of people living in the home, type of heating, having a smoker in the home, and 8 indicators of socioeconomic status, maternal education and material hardship (data not shown) (36) . There was no significant interaction by child sex (data not shown).
Seroatopy measured within one year was available for 88% of observations (n=274/313) from 217 children with 31% of measures classified as seroatopic at their FeNO observation (n=86/274). Adjusting for seroatopy did not substantially alter the estimates for the individual phthalate metabolites (Table 2 ). In sensitivity analyses similar results were seen when restricting to seroatopy measured on the day of FeNO collection (n=160, online supplement Table E4 ).
In an adjusted multi-pollutant model of FeNO including concentrations of all four metabolites (MEP, MnBP, MBzP, and MEHHP) that was also adjusted for seroatopy, MEP and MBzP remained statistically significant independent predictors of FeNO with similar effect size estimates to those in the single metabolite models as shown in Table 2 . While MEHHP concentrations remained non-significant as in the single metabolite models, the single-metabolite beta estimate for MnBP decreased from 0.080 in the seroatopy adjusted model to a beta of -0.016 in the multi-pollutant model and was no longer statistically significantly associated with FeNO after adjusting for the other phthalate metabolite concentrations (p=0.77). Therefore, the MnBP association with FeNO seen in the single phthalate model may be due to the high correlation between MnBP and MBzP (Spearman's correlation = 0.68). In the adjusted four-pollutant model, a log-unit higher concentration of MEP and MBzP was associated with a 6.6% increase (95% CI 0.5% to 13.1%, p=0.034) and a 8.7% increase (95% CI 1.9% to 16.0%, p=0.011) in FeNO respectively after adjusting for all four metabolite concentrations, seroatopy, specific gravity, age, sex, race/ethnicity, time of day of FeNO collection and ambient NO.
Interaction between phthalate metabolites and seroatopy or wheeze
There was no direct association between the urinary concentrations of any of the four metabolites with incident seroatopy or reported wheeze (see online supplement). As seen in Figure 2 , FeNO was higher among children with seroatopy (geometric mean (GM) 11.6 ppb, n=86) than those without seroatopy (GM 7.5 ppb, n=188; p<0.001). Although the slopes of the MEP or MBzP and FeNO associations were slightly larger among those with seroatopy than those without seroatopy ( Figure 2) ; testing interaction terms in the GEE models showed that the differences in the slopes were not statistically significant (p=0.51 and p=0.60).
We also assessed the interaction between phthalate concentrations and wheeze using data p=0.016, n=284). In sensitivity analyses, this interaction was stronger and remained significant when restricted to ISAAC wheeze questionnaires asked on the same day as FeNO collection (p=0.011, n=187).
As a further exploration of the interaction between phthalates and wheeze, a latent class growth analysis was used to model the probability of wheezing in the past three months. This LCGA included 7048 questionnaires on report of wheeze in the past 3 months from 15 timepoints between 3 months and 9 years of age in a larger subset (n=689) of the children in the CCCEH study (31) . The resulting predicted probability of wheezing was available for all n=313 observations and ranged from 0.01 to 0.66 although they were highly skewed with a median of 0.04, a 75 th percentile of 0.08, and a 95 th percentile of 0.44. There was no evidence of interaction between concentrations of MEP, MnBP, or MEHHP and LCGA predicted probability of wheeze on FeNO. However, as in the analysis using a dichotomous ISAAC wheeze question, the interaction between MBzP urinary concentrations and the LCGA probability of wheezing on
FeNO was positive and highly significant (p=0.006). The association between concentrations of MBzP and FeNO was of a larger magnitude among those with a higher probability of wheezing ( Figure 4 ).
Discussion
In this observational study of children, urinary concentrations of three phthalate metabolites (MEP, MnBP, and MBzP) were associated positively with FeNO measured on the same day in separate adjusted models. This is the first population-based study to show an association between phthalate exposure and this measure of airway inflammation. All three associations remained largely unchanged after adjusting for seroatopy. When all four metabolites (MEP, MnBP, MBzP, MEHHP) were included in the same adjusted model, MEP and MBzP remained independent predictors of higher FeNO, while concentrations of MnBP, which are highly correlated with concentrations of MBzP, were no longer associated with FeNO. These results suggest that urinary biomarkers of exposure to two phthalates, believed to have substantial inhalational exposure, are associated with a measure of subclinical airway inflammation in children.
This observational study of children is the first to report a positive association between biomarkers of exposure to phthalates and FeNO. The methodology for measuring FeNO allows for non-invasive collection and measurement of NO produced by resident airway cells in response to inflammatory cytokines and mediators (37) . While its diagnostic utility in children remains debated (37, 38) , FeNO has been established as a biomarker of airway inflammation in response to air pollutants with more than a decade of epidemiology studies (20, 22, 23, 39, 40 ).
In population-based studies, the majority of asthmatics have mild disease with infrequent exacerbations, making temporal associations between environmental exposures and exacerbations difficult to establish. Elevated FeNO reflects eosinophilic airway inflammation in response to known asthma triggers and has been associated both with increased symptoms among asthmatics and with the development of asthma among non-asthmatic children (20, 41) .
As such, it offers an objective biomarker to detect subclinical variations in airway inflammation reflecting increased risk for exacerbation. Our findings of associations with phthalates and FeNO contrast with those from two small controlled chamber studies of adults exposed to polyvinyl chloride surfaces in which there was no increase in post-versus pre-challenge FeNO (42, 43) .
We hypothesized that children with report of wheeze in the last 12 months would be more susceptible to airway inflammation triggered by phthalate exposures than the nonwheezing children in our cohort. We observed a positive interaction between MBzP urinary concentrations and wheeze. There was also a positive interaction between urinary concentrations of MBzP and the probability of wheezing predicted from a latent class growth analysis of questionnaire data, suggesting that the MBzP and FeNO association is stronger among a subset of children who wheeze. Although wheeze itself is episodic, the LCGA-based prediction was based on the pattern of wheezing at up to 15 time points between 3 months and 9 years of age and may offer a more stable indication of children with airway disease than a single questionnaire response. An additional advantage of the LCGA-based wheeze prediction is that it could be computed for all observations and derived a continuous variable and therefore also may be more informative than a dichotomous classification. Direct comparison of our two wheezing measures is difficult, because the LCGA derived probability of wheeze over 3 months was based on a different question than the ISAAC wheeze and uncertainty estimates from the original LCGA model were not propagated into the LCGA-based probability of wheeze. The consistency of these observations using two different measures of wheeze lends support to these findings.
Although steroids affect the strength of the correlation between FeNO and wheeze (44) *P<0.05 difference in demographic variables between children with and without seroatopy or with and without wheeze. † Potentially time varying variables (e.g., wheeze and seroatopy) are reported for the children at the youngest age measured among the children with metabolites and FeNO measured at multiple ages. ‡ Specific IgE to dust mite, cockroach, or mouse allergens (≥0.35 IU/ml) in serum collected within one year of the FeNO measure. § Children with a report of wheeze on the ISAAC questionnaire following FeNO collection were classified as having wheezed. ¶ African-American race and Dominican Republic ethnicity were reported for the mother.
**
Mother reported at closest questionnaire that she and her family could not afford needed food, rent, clothing or medical care or that gas/electricity was suspended because of bill non-payment in the previous 6 months. † † Corrected for updated CDC standards as of January 2012 as described in the online supplement. 
Sample collection of FeNO
The protocol for FeNO collection has been described previously following guidelines from the American Thoracic Society (E3-E5). FeNO was collected in mylar bags after diverting to discard the first portion of the breath, approximately 1-3 seconds of exhalation of dead-space air, using an offline device (#CBSK 01400, GE Instruments, Boulder, CO). Children were coached through attempts to gather three valid maneuvers in which they exhaled at 83 ml/sec and inhaled through the NO scrubber. Samples were not considered valid and were excluded if the child 1) did not inhale through the NO scrubber and the ambient NO was >20 ppb, or 2) if ambient NO was >100 ppb (regardless of inhalation through scrubber). Data analysis used the mean of the valid attempts for each child during their visit.
Use of glucocorticoid steroids
At 
Postnatal urinary phthalates and incident seroatopy
While exposure to phthalates is likely to occur at all ages, a cross-sectional analysis with seroatopy may be inappropriate as the onset of allergic sensitization to aeroallergens is largely non-reversible and incidence is spread over the childhood period. However, repeated sampling of both phthalate metabolites urinary concentrations and seroatopy at various ages in this cohort makes possible an analysis of the association of childhood exposure with later incident seroatopy. This analysis can be done on a larger subset of children in the CCCEH study without restricting to those with measures of FeNO.
Concentrations of phthalate metabolites were measured in urine samples collected at age 3 and 5 years at the CDC as previously described. Seroatopy at a particular age was defined as specific IgE (≥0.35 IU/ml) to dust mite, cockroach, or mouse in samples from age 2 or 3 years (combined), age 5, or age 7. Incident seroatopy at age 5 or 7 years was defined as new cases of seroatopy among those who had one or more samples collected at previous ages and had no previous positive specific IgE results. Thus, a child developing seroatopy between age 3 and 5
would not be included in the susceptible population at age 7. Logistic regression models using generalized estimating equations modeled incident seroatopy at age 5 and 7 and phthalate metabolite urinary concentrations two years prior adjusting for specific gravity, sex, race/ethnicity, age at atopy measure, and time between the phthalate and atopy measure.
Results
Time of day and FeNO concentration
We explored the association between the time of day that FeNO was collected and FeNO concentration. There was no association between time of day and FeNO after adjusting for covariates (particularly ambient NO concentration) and allowing for flexibility in the shape of the association. Using a generalized additive mixed model with penalized splines, the parameter estimating the time of day of FeNO collection simplifies to a non-significant linear term (p=0.41) in a model adjusted for our set of other potential confounders (sex, race/ethnicity, age, and ambient NO concentration).
Postnatal urinary phthalates and incident seroatopy
There were 240 children with phthalate metabolites measured at age 3 years, no seroatopy at age 2 or 3, and a seroatopy measure at age 5, as well as 198 children with phthalate metabolites measured at age 5, no seroatopy in available samples from ages 2, 3, or 5, and a measure of seroatopy at age 7. Overall, there were 438 observations with these available data from 321 children. There were 41/240 (17%) and 34/198 (17%) new incident cases of seroatopy at age 5 and 7 years respectively. There was no association between any of the individual metabolites of interest and incident seroatopy in the following two years (Supplemental Materials Table E2 ).
We have reported previously that there was no association between a maternal urinary concentration of MBzP and the development of seroatopy by age 5 years in this population (E6) .
In this analysis we also did not see any association between phthalate metabolite concentrations measured at age 3 or age 5 and the development of seroatopy over the following two years.
Phthalate metabolites and wheeze
In both the subset with FeNO data and a larger group of children from the full CCCEH cohort with available data, there was no consistent association between individual urinary concentrations of the four metabolites of interest and concurrent report of wheeze at age 5 or at age 7 (Supplemental Materials Table E3 ). Table E1 . Demographics of mothers and child at enrollment among those included in the analyses (n=244) and those recruited who were not included.
Included (n=244)
Enrolled but not included (n=483) Table E4 .
*All models adjusted for specific gravity, seroatopy, sex, race/ethnicity, age, time of day of FeNO collection and ambient NO concentration Table E5 .
*Models adjusted for specific gravity, age at atopy measure, time since phthalate measure, sex, and race/ethnicity Footnote for Table E6 .
*Models adjusted for specific gravity, sex, and race/ethnicity
